ADMA Adma Biologics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ADMA

Price (delayed)

$7.895

Market cap

$1.83B

P/E Ratio

11.44

Dividend/share

N/A

EPS

$0.69

Enterprise value

$1.89B

?
Relative Growth: Rel. Growth: 49
Relative Strength: Rel. Strength: 2
Relative Valuation: Rel. Valuation: 70
Relative Profitability: Rel. Profitability: 90

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at ...

Highlights
The price to earnings (P/E) is 44% lower than the last 4 quarters average of 20.0
The gross profit has grown by 29% YoY and by 7% from the previous quarter
The EPS has declined by 22% year-on-year but it has grown by 11% since the previous quarter
The company's net income fell by 20% YoY but it rose by 13% QoQ
The company's debt has surged by 170% QoQ and by 169% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.admabiologics.com
Peers: NVAX RGEN CVM

Key stats

What are the main financial stats of ADMA

ADMA stock price

How has the Adma Biologics stock price performed over time
Intraday
1.74%
1 week
-0.44%
1 month
-23.42%
1 year
-61.17%
YTD
-56.72%
QTD
-12.38%

Financial performance

How have Adma Biologics's revenue and profit performed over time
Revenue
$509.86M
Gross profit
$312.42M
Operating income
$214.84M
Net income
$165.35M
Gross margin
61.3%
Net margin
32.4%
Adma Biologics's operating income has increased by 41% YoY and by 12% QoQ
The gross profit has grown by 29% YoY and by 7% from the previous quarter
The company's net margin fell by 28% YoY but it rose by 13% QoQ
Adma Biologics's operating margin has increased by 27% YoY and by 12% QoQ

Price vs fundamentals

How does ADMA's price correlate with its fundamentals

Growth

What is Adma Biologics's growth rate over time

Valuation

What is Adma Biologics stock price valuation
ADMA P/E details
P/E
11.44
P/B
4.82
P/S
3.66
EV/EBIT
8.85
EV/EBITDA
8.53
EV/Sales
3.71
The price to earnings (P/E) is 44% lower than the last 4 quarters average of 20.0
The EPS has declined by 22% year-on-year but it has grown by 11% since the previous quarter
The price to book (P/B) is 44% lower than the last 4 quarters average of 8.4 and 35% lower than the 5-year quarterly average of 7.3
The equity has declined by 18% since the previous quarter but it has increased by 4.5% year-on-year
ADMA's price to sales (P/S) is 51% lower than its last 4 quarters average of 7.3 and 37% lower than its 5-year quarterly average of 5.7
ADMA's revenue is up by 11% year-on-year

Efficiency

How efficient is Adma Biologics business performance
ADMA's ROE is down by 46% YoY but it is up by 11% QoQ
The company's return on assets fell by 41% YoY but it rose by 5% QoQ
The return on sales has grown by 26% year-on-year and by 13% since the previous quarter
The company's return on invested capital rose by 2.6% QoQ and by 2.1% YoY

Dividends

What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADMA.

Financial health

How did Adma Biologics financials performed over time
Adma Biologics's total assets is 142% more than its total liabilities
Adma Biologics's total liabilities has surged by 100% YoY and by 87% QoQ
Adma Biologics's total assets has increased by 30% YoY and by 7% from the previous quarter
The company's debt is 49% lower than its equity
The company's debt has surged by 170% QoQ and by 169% YoY
Adma Biologics's debt to equity has surged by 155% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.